Obesity during the menopausal transition: how to break negative connections and prevent consequences?

1. Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., Трошина Е.А., Мазурина Н.В., Ершова Е.В., Комшилова К.А., Андреева Е.Н., Анциферов М.Б., Бирюкова Е.В., Бордан Н.С., Вагапова Г.Р., Волкова А.Р., Волкова Н.И., Волынкина А.П., Дзгоева Ф.Х., Киселева Т.П., Неймарк А.Е., Романцова Т.И., Руяткина Л.А., Суплотова Л.А., Халимов Ю.Ш., Яшков Ю.И. Ожирение. Клинические рекомендации. Consilium Medicum. 2021; 23(4): 311-25. [Dedov I.I., Mokrysheva N.G., Mel’nichenko G.A., Troshina E.A., Mazurina N.V., Ershova E.V., Komshilova K.A., Andreeva E.N., Antsiferov M.B., Biriukova E.V., Bordan N.S., Vagapova G.R., Volkova A.R., Volkova N.I., Volynkina A.P., Dzgoeva F.Kh., Kiseleva T.P., Neimark A.E., Romantsova T.I., Ruiatkina L.A., Suplotova L.A., Khalimov Iu.Sh., Yashkov Iu.I. Obesity. Clinical guidelines. Consilium Medicum. 2021; 23(4): 311-25. https://dx.doi.org/10.26442/20751753.2021.4.200832.
2. Valenzuela P.L., Carrera-Bastos P., Castillo-García A., Lieberman D.E., Santos-Lozano A., Lucia A. Obesity and the risk of cardiometabolic diseases. Nat. Rev. Cardiol. 2023; 20(7): 475-94. https://dx.doi.org/10.1038/s41569-023-00847-5.
3. World Obesity Atlas 2022. Available at: https://www.worldobesity.org
4. Dedov I., Shestakova M., Benedetti M.M., Simon D., Pakhomov I., Galstyan G. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res. Clin. Pract. 2016; 115: 90-5. https://dx.doi.org/10.1016/j.diabres.2016.02.010.
5. Kontsevaya A., Shalnova S., Deev A., Breda J., Jewell J., Rakovac I. et al. Overweight and obesity in the Russian population: prevalence in adults and association with socioeconomic parameters and cardiovascular risk factors. Obes. Facts. 2019; 12(1): 103-14. https://dx.doi.org/10.1159/000493885.
6. Santoro N., Roeca C., Peters B.A., Neal-Perry G. The menopause transition: signs, symptoms, and management options. J. Clin. Endocrinol. Metab. 2021; 106(1): 1-15. https://dx.doi.org/10.1210/clinem/dgaa764.
7. El Khoudary S.R., Greendale G., Crawford S.L., Avis N.E., Brooks M.M., Thurston R.C. et al. The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN). Menopause. 2019; 26(10): 1213-27. https://dx.doi.org/10.1097/GME.0000000000001424.
8. Opoku A.A., Abushama M., Konje J.C. Obesity and menopause. Best. Pract. Res. Clin. Obstet. Gynaecol. 2023; 88: 102348. https://dx.doi.org/10.1016/j.bpobgyn.2023.102348.
9. Алфёрова В.И., Мустафина С.В. Адипоцитокины сквозь призму метаболических фенотипов человека. Доктор Ру. 2023; 22(4):18-23. [Alferova V.I., Mustafina S.V. Adipocytokines through the prism of human metabolic phenotypes. Doctor.Ru. 2023; 22(4): 18-23. (in Russian)]. https://dx.doi.org/10.31550/1727-2378-2023-22-4-18-23.
10. Мустафина С.В., Алферова В.И., Рымар О.Д., Щербакова Л.В., Денисова Д.В., Каштанова Е.В., Винтер Д.А., Рагино Ю.И. Уровни адипоцитокинов и их ассоциации с клинико-лабораторными показателями у женщин 25-44 лет с разными метаболическими фенотипами. Эндокринология: новости, мнения, обучение. 2023;12(2): 23-35. [Mustafina S.V., Alferova V.I., Rymar O.D., Shcherbakova L.V., Denisova D.V., Kashtanova E.V., Vinter D.A.,Ragino Yu.I. Adipocytokine levels and their associations with clinical and laboratory parameters in women aged 25-44 years with different metabolic phenotypes. Endocrinology: News, Opinions, Training. 2023; 12(2): 23-35.(in Russian)]. https://dx.doi.org/10.33029/2304-9529-2023-12-2-23-35.
11. Crawford S.L. Is metabolically healthy obesity really healthy? Menopause. 2020; 27(6): 628-9. https://dx.doi.org/10.1097/GME.0000000000001551.
12. Eckel N., Li Y., Kuxhaus O., Stefan N., Hu F.B., Schulze M.B. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses' Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 2018; 6(9): 714-24. https://dx.doi.org/10.1016/S2213-8587(18)30137-2.
13. Bluher M. Obesity: global epidemiology and pathogenesis. Nat. Rev. Endocrinol 2019; 15(5): 288-98. https://dx.doi.org/10.1038/s41574-019-0176-8.
14. Оразов М.Р., Радзинский В.Е., Хамошина М.Б., Муллина И.А., Артеменко Ю.С., Рябова В.А. Metabesity у женщин: долгосрочные последствия для здоровья. Доктор Ру. 2023; 22(1): 11-5. [Orazov M.R., Radzinsky V.E., Khamoshina M.B., Mullina I.A., Artemenko Yu.S., Ryabova V.A. Metabesity in women: long-term health effects. Doctor.Ru. 2023; 22(1): 11-5. (in Russian)]. https://dx.doi.org/10.31550/1727-2378-2023-22-1-11-15.
15. Chen G.C., Arthur R., Iyengar N.M., Kamensky V., Xue X., Wassertheil-Smoller S. et al. Association between regional body fat and cardiovascular disease risk among postmenopausal women with normal body mass index. Eur. Heart J. 2019; 40(34): 2849-55. https://dx.doi.org/10.1093/eurheartj/ehz391.
16. Peters S.A.E., Bots S.H., Woodward M. Sex differences in the association between measures of general and central adiposity and the risk of myocardial infarction: results from the UK Biobank. J. Am. Heart Assoc. 2018; 7(5): e008507. https://dx.doi.org/10.1161/JAHA.117.008507.
17. Sun Y., Liu B., Snetselaar L.G., Wallace R.B., Caan B.J., Rohan T.E. et al. Association of normal-weight central obesity with all-cause and cause-specific mortality among postmenopausal women. JAMA Netw. Open. 2019; 2(7): e197337. https://dx.doi.org/10.1001/jamanetworkopen.2019.7337.
18. Шляхто Е.В., Сухих Г.Т., Серов В.Н., Дедов И.И., Арутюнов Г.П., Сучков И.А. Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ Российского кардиологического общества, Российского общества акушеров-гинекологов, Российской ассоциации эндокринологов, Евразийской ассоциации терапевтов, Ассоциации флебологов России. Акушерство и гинекология. 2023; 11: 211-32. [Shlyakhto E.V., Sukhikh G.T., Serov V.N., Dedov I.I., Arutyunov G.P., Suchkov I.A. Russian eligibility criteria for menopausal hormone therapy in patients with cardiovascular and metabolic diseases. Consensus document of the Russian Society of Cardiology, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Russian Phlebological Association. Obstetrics and Gynecology. 2023; (11): 211-32 (in Russian)]. https://dx.doi.org/10.18565/aig.2021.267.
19. Banack H.R., Bea J.W., Chen Z., Blew R.M., Nicholas S., Stefanick M. et al. Longitudinal patterns of abdominal visceral and subcutaneous adipose tissue, total body composition, and anthropometric measures in postmenopausal women: results from the Women's Health Initiative. Int. J. Obes. (Lond.) 2023; 47(4): 288-296. https://dx.doi.org/10.1038/s41366-023-01266-9.
20. Randolph J.F. Jr., Zheng H., Sowers M.R., Crandall C., Crawford S., Gold E.B. et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J. Clin. Endocrinol. Metab. 2011; 96(3): 746-54. https://dx.doi.org/10.1210/jc.2010-1746.
21. Greendale G.A., Sternfeld B., Huang M., Han W., Karvonen-Gutierrez C., Ruppert K. et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019; 4(5): e124865. https://dx.doi.org/10.1172/jci.insight.124865.
22. Greendale G.A., Han W., Finkelstein J.S., Burnett-Bowie S.M., Huang M., Martin D. et al. Changes in regional fat distribution and anthropometric measures across the menopause transition. J. Clin. Endocrinol. Metab. 2021; 106(9): 2520-34. https://dx.doi.org/10.1210/clinem/dgab389.
23. Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T. et al.; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48(1): 16-31. https://dx.doi.org/10.1093/ageing/afy169.
24. Goldstein S.R. Sarcopenic obesity: a double whammy. Menopause. 2022; 29(6): 644-5. https://dx.doi.org/10.1097/GME.0000000000001994.
25. El Khoudary S.R., Aggarwal B., Beckie T.M., Hodis H.N., Johnson A.E., Langer R.D. et al.; American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation. 2020; 142(25): e506-e532. https://dx.doi.org/10.1161/CIR.0000000000000912.
26. Ding M., Manson J.E. HDL-c and arterial calcification in midlife women: does an HDL paradox exist? Menopause. 2021; 28(3): 231-3. https://dx.doi.org/10.1097/GME.0000000000001734.
27. Sepandar F., Rashidbeygi E., Maghbooli Z., Khorrami-Nezhad L., Hajizadehoghaz M., Mirzaei K. The association between resting metabolic rate and metabolic syndrome May Be mediated by adipokines in overweight and obese women. Diabetes Metab. Syndr. 2019; 13(1): 530-4. https://dx.doi.org/10.1016/j.dsx.2018.10.012.
28. Lambrinoudaki I., Kazani A., Armeni E., Rizos D., Augoulea A., Kaparos G. et al. The metabolic syndrome is associated with carotid atherosclerosis and arterial stiffness in asymptomatic, nondiabetic postmenopausal women. Gynecol. Endocrinol. 2018; 34(1): 78-82. https://dx.doi.org/10.1080/09513590.2017.1344208.
29. Дедов И.И., Шестакова М.В., Мельниченко Г.А., Мазурина Н.В., Андреева Е.Н., Бондаренко И.З., Гусова З.Р., Дзгоева Ф.Х., Елисеев М.С., Ершова Е.В., Журавлева М.В., Захарчук Т.А., Исаков В.А., Клепикова М.В., Комшилова К.А., Крысанова В.С., Недогода С.В., Новикова А.М., Остроумова О.Д., Переверзев А.П., Роживанов Р.В., Романцова Т.И., Руяткина Л.А., Саласюк А.С., Сасунова А.Н., Сметанина С.А., Стародубова А.В., Суплотова Л.А., Ткачева О.Н., Трошина Е.А., Хамошина М.Б., Чечельницкая С.М., Шестакова Е.А., Шереметьева Е.В. Междисциплинарные клинические рекомендации «Лечение ожирения и коморбидных заболеваний». Ожирение и метаболизм. 2021; 18(1): 5-99. [Dedov I.I., Shestakova M.V., Melnichenko G.A., Mazurina N.V., Andreeva E.N., Bondarenko I.Z., Gusova Z.R., Dzgoeva F.K., Eliseev M.S., Ershova E.V., Zhuravleva M.V., Zakharchuk T.A.,Isakov V.A., Klepikova M.V., Komshilova K.A., Krysanova V.S., Nedogoda S.V., Novikova A.M., Ostroumova O.D., Pereverzev A.P., Rozhivanov R.V., Romantsova T.I., Ruyatkina L.A., Salasyuk A.S., Sasunova A.N.,Smetanina S.A., Starodubova A.V., Suplotova L.A., Tkacheva O.N., Troshina E.A., Khamoshina M.B., Chechelnitskay S.M., Shestakova E.A., Sheremet’eva E.V. Interdisciplinary Clinical Practice Guidelines "Management of obesity and its comorbidities". Obesity and metabolism. 2021; 18(1): 5-99. https://dx.doi.org/10.14341/omet12714.
30. Thurston R.C., Chang Y., Mancuso P., Matthews K.A. Adipokines, adiposity, and vasomotor symptoms during the menopause transition: findings from the Study of Women's Health Across the Nation. Fertil. Steril. 2013; 100(3): 793-800. https://dx.doi.org/10.1016/j.fertnstert.2013.05.005.
31. Huang W.Y., Chang C.C., Chen D.R., Kor C.T., Chen T.Y., Wu H.M. Circulating leptin and adiponectin are associated with insulin resistance in healthy postmenopausal women with hot flashes. PLoS One. 2017; 12(4): e0176430. https://dx.doi.org/10.1371/journal.pone.0176430.
32. Woods R., Hess R., Biddington C., Federico M. Association of lean body mass to menopausal symptoms: The Study of Women's Health Across the Nation. Women's Midlife Health. 2020; 6: 10. https://dx.doi.org/10.1186/s40695-020-00058-9.
33. Banack H.R., Wactawski-Wende J., Hovey K., Stokes A. Is BMI a valid measure of obesity in postmenopausal women? Menopause. 2018; 25(3): 307-13. https://dx.doi.org/10.1097/GME.0000000000000989.
34. Юренева С.В., Комедина В.И., Кузнецов С.Ю. Диагностические возможности антропометрических показателей для оценки ожирения у женщин в период менопаузального перехода. Акушерство и гинекология. 2022; 2: 72-9. [Yureneva S.V., Komedina V.I., Kuznetsov S.Yu. Diagnostic value of anthropometric characteristics of obesity in women during the menopause transition. Obstetrics and Gynecology. 2022; (2): 72-9 (in Russian)]. https://dx.doi.org/10.18565/aig.2022.2.72-79.
35. Marra M., Sammarco R., De Lorenzo A., Iellamo F., Siervo M., Pietrobelli A. et al. Assessment of body composition in health and disease using Bioelectrical Impedance Analysis (BIA) and Dual Energy X-Ray Absorptiometry (DXA): A critical overview. Contrast Media Mol. Imaging. 2019; 2019: 3548284. https://dx.doi.org/10.1155/2019/3548284.
36. Ross R., Neeland I.J., Yamashita S., Shai I., Seidell J., Magni P. et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat. Rev. Endocrinol. 2020; 16(3): 177-89. https://dx.doi.org/10.1038/s41574-019-0310-7.
37. Christakoudi S., Tsilidis K.K., Muller D.C., Freisling H., Weiderpass E., Overvad K. et al. A Body Shape Index (ABSI) achieves better mortality risk stratification than alternative indices of abdominal obesity: results from a large European cohort. Sci. Rep. 2020; 10(1): 14541. https://dx.doi.org/10.1038/s41598-020-71302-5.
38. Ebrahimi M., Seyedi S.A., Nabipoorashrafi S.A., Rabizadeh S., Sarzaeim M., Yadegar A. et al. Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Lipids Health Dis. 2023; 22(1): 41. https://dx.doi.org/10.1186/s12944-023-01802-6.
39. Davis S.R., Pinkerton J., Santoro N., Simoncini T. Menopause-biology, consequences, supportive care, and therapeutic options. Cell. 2023; 186(19): 4038-58. https://dx.doi.org/10.1016/j.cell.2023.08.016.
40. Anderson D.J., Chung H.F., Seib C.A., Dobson A.J., Kuh D., Brunner E.J. et al. Obesity, smoking, and risk of vasomotor menopausal symptoms: a pooled analysis of eight cohort studies. Am. J. Obstet. Gynecol. 2020; 222(5): 478.e1-478.e17. https://dx.doi.org/10.1016/j.ajog.2019.10.103.
41. Moore S.R., Cabre H.E., Smith-Ryan A.E. Body composition, physical activity, and menopause symptoms: how do they relate? Menopause. 2024;31(4):336-41. https://dx.doi.org/10.1097/GME.0000000000002334.
42. Muscogiuri G., Verde L., Sulu C., Katsiki N., Hassapidou M., Frias-Toral E. et al. Mediterranean Diet and Obesity-related Disorders: What is the Evidence? Curr. Obes. Rep. 2022; 11(4): 287-304. https://dx.doi.org/10.1007/s13679-022-00481-1.
43. Kuk J.L., Kamran E., Wharton S. Association between weight-loss history and weight loss achieved in clinical obesity management: Retrospective chart review. Obesity (Silver Spring). 2022; 30(10): 2071-8. https://dx.doi.org/10.1002/oby.23530.
44. Roth G.A., Mensah G.A., Johnson C.O., Addolorato G., Ammirati E., Baddour L.M. et al.; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study. J. Am. Coll. Cardiol. 2020; 76(25): 2982-3021. https://dx.doi.org/10.1016/j.jacc.2020.11.010.
45. Lee I.M., Shiroma E.J., Kamada M., Bassett D.R., Matthews C.E., Buring J.E. Association of step volume and intensity with all-cause mortality in older women. JAMA Intern. Med. 2019; 179(8): 1105-12. https://dx.doi.org/10.1001/jamainternmed.2019.0899.
46. Banach M., Lewek J., Surma S., Penson P.E., Sahebkar A., Martin S.S. et al. The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis. Eur. J. Prev. Cardiol. 2023; 30(18): 1975-85. https://dx.doi.org/10.1093/eurjpc/zwad229.
47. Papadakis G.E., Hans D., Gonzalez Rodriguez E., Vollenweider P., Waeber G., Marques-Vidal P. et al. Menopausal hormone therapy is associated with reduced total and visceral adiposity: The OsteoLaus Cohort. J. Clin. Endocrinol. Metab. 2018; 103(5): 1948-57. https://dx.doi.org/10.1210/jc.2017-02449.
48. Kim S.W., Kim R. The association between hormone therapy and sarcopenia in postmenopausal women. The Korea National Health and Nutrition Examination Survey, 2008-2011. Menopause. 2020; 27(5): 506-11. https://dx.doi.org/10.1097/GME.0000000000001509.
49. Park Y.M., Keller A.C., Runchey S.S., Miller B.F., Kohrt W.M., Van Pelt R.E. et al. Acute estradiol treatment reduces skeletal muscle protein breakdown markers in early- but not late-postmenopausal women. Steroids. 2019; 146: 43-9. https://dx.doi.org/10.1016/j.steroids.2019.03.008.
50. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022; 29(7): 767-94. https://dx.doi.org/10.1097/GME.0000000000002028.
51. Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021; 24(3): 204-21. [Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.А. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021; 24(3): 204-21. (in Russian)]. https://dx.doi.org/10.14341/DM12759.
52. Salpeter S.R., Walsh J.M., Ormiston T.M., Greyber E., Buckley N.S., Salpeter E.E. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes. Metab. 2006; 8(5): 538-54. https://dx.doi.org/10.1111/j.1463-1326.2005.00545.x.
53. Slopien R., Wender-Ozegowska E., Rogowicz-Frontczak A., Meczekalski B., Zozulinska-Ziolkiewicz D., Jaremek J.D. et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018; 117: 6-10. https://dx.doi.org/10.1016/j.maturitas.2018.08.009.
54. Tankó L.B., Christiansen C. Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J. Intern. Med. 2005; 258(6): 544-53. https://dx.doi.org/10.1111/j.1365-2796.2005.01571.x.
55. Инструкция по медицинскому применению лекарственного препарата Анжелик® (Angeliq®) от 20.03.2024. [Instructions for the medical use of the drug Angeliq® dated 03/20/2024. (in Russian)].
56. Hurtado M.D., Tama E., Fansa S., Ghusn W., Anazco D., Acosta A. et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024; 31(4): 266-74. https://dx.doi.org/10.1097/GME.0000000000002310.

Received 15.11.2024

Accepted 21.11.2024